ALCLS Cellectis SA

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social

(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers)

PARIS, 16 mai 2024 (GLOBE NEWSWIRE) --

Place de cotation : Euronext Growth

ISIN code: FR0010425595

DateNombre total d’actions

composant le capital social		Nombre total de droits de vote
03/05/202499 955 53587 891 239



Pour de plus amples informations sur Cellectis, veuillez contacter :        

Contact média :        

Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93,

Contacts pour les relations avec les investisseurs :        

Arthur Stril, Interim Chief Financial Officer, +1 (347) 809 5980,         

Sandya von der Weid, Associate Director, LifeSci Advisors, 8      

Pièce jointe



EN
16/05/2024

Underlying

ALCLSCellectis SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cellectis SA

Ahmed Ben Salem ... (+2)
  • Ahmed Ben Salem
  • Baptiste Lebacq
FRA FRAPORT AG
ETL EUTELSAT COMMUNICATIONS SA
SCR SCOR SE
OERL OC OERLIKON CORPORATION AG
ALCLS CELLECTIS SA
BOSS HUGO BOSS AG
NOEJ NORMA GROUP SE
ERA ERAMET SA
LNZ LENZING AG
NDA AURUBIS AG
KRN KRONES AG
COFA COFACE SA
TRP TERAPLAST
MAU ETABLISSEMENTS MAUREL & PROM SA
SFQ SAF-HOLLAND SE
ADTN ADTRAN HOLDINGS INC
STM STABILUS SE
08/05/25 August 5, 2025 1 EN
Ahmed Ben Salem ... (+2)
  • Ahmed Ben Salem
  • Baptiste Lebacq
FRA FRAPORT AG
ETL EUTELSAT COMMUNICATIONS SA
SCR SCOR SE
OERL OC OERLIKON CORPORATION AG
ALCLS CELLECTIS SA
BOSS HUGO BOSS AG
NOEJ NORMA GROUP SE
ERA ERAMET SA
LNZ LENZING AG
NDA AURUBIS AG
KRN KRONES AG
COFA COFACE SA
TRP TERAPLAST
MAU ETABLISSEMENTS MAUREL & PROM SA
SFQ SAF-HOLLAND SE
ADTN ADTRAN HOLDINGS INC
STM STABILUS SE
08/05/25 August 5, 2025 1 FR
Martial Descoutures ... (+2)
  • Martial Descoutures
  • Oussema Denguir
08/05/25 August 5, 2025 1 EN
Martial Descoutures ... (+2)
  • Martial Descoutures
  • Oussema Denguir
08/05/25 August 5, 2025 1 FR
 PRESS RELEASE
Free
ALCLS CELLECTIS SA

Cellectis Reports Second Quarter 2025 Financial Results & Business Upd...

Cellectis Reports Second Quarter 2025 Financial Results & Business Updates Cellectis to host an Investor R&D Day in New York City on October 16, 2025: Phase 1 dataset and late-stage development strategy for lasme-cel (UCART22) in r/r B-ALL to be presented End-of-Phase 1 meetings with FDA & EMA for lasme-cel (UCART22) in r/r B-ALL completed in July 2025; on track to launch pivotal Phase 2 in H2 2025  Servier arbitration: arbitral decision expected to be rendered on or before December 15, 2025 eti-cel (UCART20x22): Phase 1 study in r/r NHL ongoing with readout expected in late 2025  AstraZene...

August 4, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch